Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M. Cavo; L. Pantani; A. Pezzi; M. T. Petrucci; F. Patriarca; F. Di Raimondo; G. Marzocchi; M. Galli; V. Montefusco; E. Zamagni; B. Gamberi; P. Tacchetti; A. Brioli; A. Palumbo; P. Sonneveld

doi:10.1038/leu.2015.274

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M. Cavo, L. Pantani, A. Pezzi, M. T. Petrucci, F. Patriarca, F. Di Raimondo, G. Marzocchi, M. Galli, V. Montefusco, E. Zamagni, B. Gamberi, P. Tacchetti, A. Brioli, A. Palumbo, P. Sonneveld

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2429-2431
Number of pages	3
Journal	Leukemia
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/leu.2015.274
Publication status	Published - Dec 1 2015

ASJC Scopus subject areas

Hematology
Cancer Research
Anesthesiology and Pain Medicine

Access to Document

10.1038/leu.2015.274

Cite this

Cavo, M., Pantani, L., Pezzi, A., Petrucci, M. T., Patriarca, F., Di Raimondo, F., Marzocchi, G., Galli, M., Montefusco, V., Zamagni, E., Gamberi, B., Tacchetti, P., Brioli, A., Palumbo, A., & Sonneveld, P. (2015). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia, 29(12), 2429-2431. https://doi.org/10.1038/leu.2015.274

Cavo, M, Pantani, L, Pezzi, A, Petrucci, MT, Patriarca, F, Di Raimondo, F, Marzocchi, G, Galli, M, Montefusco, V, Zamagni, E, Gamberi, B, Tacchetti, P, Brioli, A, Palumbo, A & Sonneveld, P 2015, 'Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma', Leukemia, vol. 29, no. 12, pp. 2429-2431. https://doi.org/10.1038/leu.2015.274

@article{5f95221004054c718cae0446415dabdf,

title = "Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma",

author = "M. Cavo and L. Pantani and A. Pezzi and Petrucci, {M. T.} and F. Patriarca and {Di Raimondo}, F. and G. Marzocchi and M. Galli and V. Montefusco and E. Zamagni and B. Gamberi and P. Tacchetti and A. Brioli and A. Palumbo and P. Sonneveld",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/leu.2015.274",

language = "English",

volume = "29",

pages = "2429--2431",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

AU - Cavo, M.

AU - Pantani, L.

AU - Pezzi, A.

AU - Petrucci, M. T.

AU - Patriarca, F.

AU - Di Raimondo, F.

AU - Marzocchi, G.

AU - Galli, M.

AU - Montefusco, V.

AU - Zamagni, E.

AU - Gamberi, B.

AU - Tacchetti, P.

AU - Brioli, A.

AU - Palumbo, A.

AU - Sonneveld, P.

PY - 2015/12/1

Y1 - 2015/12/1

UR - http://www.scopus.com/inward/record.url?scp=84951567534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951567534&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.274

DO - 10.1038/leu.2015.274

M3 - Article

C2 - 26442610

AN - SCOPUS:84951567534

VL - 29

SP - 2429

EP - 2431

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this